Correspondence 0001193125-24-107265 from Allogene Therapeutics, Inc. (ALLO) (CIK 0001737287) (ALLO)
Allogene Therapeutics, Inc. (ALLO) (CIK 0001737287)
Date: April 23, 2024 · CIK: 0001737287 · Accession: 0001193125-24-107265
AI Filing Summary & Sentiment
File numbers found in text: 333-277951
Letter
CORRESP - Acceleration request
ALLOGENE THERAPEUTICS, INC.
210 East Grand Avenue
South San Francisco, CA 94080
April 23, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C.
Attn: Tyler Howes
RE: Allogene Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 14, 2024
File No. 333-277951
Ladies and Gentlemen:
Allogene Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on April 25, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Charles J. Bair of Cooley LLP and Asa M. Henin of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Charles J. Bair at (858) 550-6142, or in his absence, Asa M. Henin at (858) 550-6104.
Very truly yours,
ALLOGENE THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP - Acceleration request ALLOGENE THERAPEUTICS, INC. 210 East Grand Avenue South San Francisco, CA 94080 April 23, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes RE: Allogene Therapeutics, Inc. Registration Statement on Form S-3 Filed March 14, 2024 File No. 333-277951 Ladies and Gentlemen: Allogene Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on April 25, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Charles J. Bair of Cooley LLP and Asa M. Henin of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Charles J. Bair at (858) 550-6142, or in his absence, Asa M. Henin at (858) 550-6104. Very truly yours, ALLOGENE THERAPEUTICS, INC. By: /s/ David Chang Name: David Chang Title: President and Chief Executive Officer cc: Geoffrey Parker, Allogene Therapeutics, Inc. Charles J. Bair, Cooley LLP Asa M. Henin, Cooley LLP